WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma
Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004: 44; 109-115.
WT1 is expressed in serous, but not in endometriod, clear cell or mucinous carcinomas of the peritioneum, Fallopian tube, ovaries and endometrium
Zhang PJ, Williams E, Pasha T, Acs G. WT1 is expressed in serous, but not in endometriod, clear cell or mucinous carcinomas of the peritioneum, Fallopian tube, ovaries and endometrium. Modern Pathol. 2003: 16; 216a.
Immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas
Goldstein NS, Uzieblo AWT. 1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am. J. Clin. Pathol. 2002: 117; 541-5.
Differential expression of WT-1 antibody in serous carcinomas based on primary site
Eusher ED, Malpica A, Deavers MT, Silva EG. Differential expression of WT-1 antibody in serous carcinomas based on primary site. Modern Pathol. 2003: 16; 189a.
Wilms tumour gene immunoreactivity in primary serous carcinomas of the Fallopian tube, ovary, endometrium and peritoneum
Hashi A, Yuminamochi T, Murata S-I, Iwamoto H, Honda T, Hoshi K. Wilms tumour gene immunoreactivity in primary serous carcinomas of the Fallopian tube, ovary, endometrium and peritoneum. Int. J. Gynecol. Pathol. 2003: 22; 374-7.
WT-1 expression in ovarian epithelial tumors and endometrial serous carcinoma
Kiyokawa T, Kanestsuna Y, Haralda T, Sasaki M, Suzuki M, Kawakami M. WT-1 expression in ovarian epithelial tumors and endometrial serous carcinoma. Modern Pathol. 2004: 17 (Suppl. 1); 200a.